

8 April 2022

To:

**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

GLENMARK PHARMACEUTICALS LIMITED (THE "ISSUER")

U.S.\$200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities due 2022
ISIN: XS1426780125
Common Code: 142678012
(the "**Bonds**")

NOTICE OF REDEMPTION

Pursuant to, and in accordance with, the terms of the trust deed dated 28 June 2016 (the "**Trust Deed**") constituting the Bonds, the Issuer has elected to redeem and will redeem the Notes in full on 9 May 2022 (the "**Redemption Date**") at the Early Redemption Amount pursuant to Condition 8.2 (*Redemption at the option of the Issuer*) of the terms and conditions of the Bonds.

The Early Redemption Amount is US\$942,860.24 plus interest accrued but unpaid to the Redemption Date. The Bonds will be cancelled as of the Redemption Date and interest will cease to accrue on and after the Redemption Date.

Upon the redemption and cancellation of the Bonds, the Bonds will be delisted from the Singapore Exchange Securities Trading Limited.

Capitalized terms used and not otherwise defined herein shall have the meaning given to them in the Trust Deed.

No representation is made as to, and the Issuer, the Trustee and the Paying Agents are not responsible for, the correctness or accuracy of the ISIN or Common Code listed in this Notice of Redemption or printed on the Bonds.

This announcement is for informational purposes only and shall not constitute an offer to purchase the Bonds.

8 April 2022

THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR BROKER, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER.

This announcement is not an offer to purchase, a solicitation of an offer to purchase, an offer to sell, or a solicitation of an offer to sell, the Bonds. This announcement does not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law. This announcement is not for release, publication or

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

distribution in or into, or to any person resident and/or located in, any jurisdiction where such release, publication or distribution is unlawful.

This announcement does not constitute an offer to sell or the solicitation of an offer to purchase any securities in the United States, India or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus which will contain detailed information about the Company and its management, as well as its financial statements. No public offering of securities is to be made by the Company in the United States.

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com